glp-1 ban FDA is moving to restrict mass-marketed compounded products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Should GLP-1 agonists like Ozempic

Overall, about one in five (22%) adults who are not currently taking GLP-1 drugs (88% of the public) say they would be interested in taking a GLP-1 drug to lose weight, including just 7% who say they would be very interested. This rises to four in ten (43%) among adults who are not currently taking a GLP-1 but report being diagnosed as overweight or obese in the past five years, and about one in four (27%) among those who say they have been diagnosed with diabetes or heart disease

How Key Electrolytes Are Affected by GLP-1 Use Researchers havent investigated the exact effects a GLP-1 RA medication might have on electrolytes, let alone the different versions

Keep up the great work

Nevertheless, Novo Nordisk and Eli Lilly are positioned at the forefront, striving to capitalise on their already successful GLP-1R portfolios and solidify their dominance in the GLP-1R market.